ReViral Drug Discovery for Respiratory Syncytial Virus (RSV)
  • ReViral is a UK-based biotechnology company with a portfolio of drugs to treat RSV infection
  • The most advanced programme, RV521, is a highly potent fusion inhibitor
  • RV521 has received top-line safety and pharmacokinetic data for Phase 1 single and multiple ascending dose (SAD and MAD) trials
  • RV521 is delivered by a convenient oral dose
  • RV521 is now in Phase 2a trial to provide clinical POC
RV521 best-in-class drug to treat RSV infections
  • RV521 is an orally available antiviral with excellent drug-like characteristics
  • Binds to the RSV fusion protein, blocking viral entry and preventing cell-to-cell spread
  • The compound demonstrates potent activity against multiple clinical strains of RSV

RSV Medical Need

  • RSV is the main cause of hospitalisation for children under the age of 5 and a major cause of hospitalisation for the elderly
  • Currently, there are no effective treatments or vaccines available against RSV
  • There is a clear unmet need for a safe and effective treatment with a simple route of administration
Meet the team...
Latest News
Positive results achieved in ReViral’s Phase IIa RSV challenge study

ReViral’s RV521 fusion inhibitor produces highly significant reduction in viral load and clinical symptoms

London, UK, 5th February...

ReViral present at OneNucleus

Reviral's Chief Operating Officer, Rachel Harland, will be delivering a presentation at Chesterford Research Park on the 15th of November as part of the OneNucleus Leadership...

ReViral at Pharma Integrates 2017

ReViral’s CEO, Eddy Littler, will be a panellist at Pharma Integrates 2017 (Biotech CEO Panel Series: Crossing the Valley of Death Between Discovery and Proof of...

Contact us...